Mereo BioPharma Group plc (FRA:MAH0)

Market Cap	57.26M -88.0%
Revenue (ttm)	426.15K -50.0%
Net Income	-35.43M
EPS	-0.22
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,150
Average Volume	908
Open	0.3590
Previous Close	0.3480
Day's Range	0.3510 - 0.3590
52-Week Range	0.3020 - 2.7700
Beta	n/a
RSI	36.30
Earnings Date	Mar 26, 2026

About Mereo BioPharma Group

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab, an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for use in the treatment of tumors. The company is also developing Navicixizumab, which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod, a p38 MAP kinase inhibitor that ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2015
• Employees: 36
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: MAH0

Financial Performance

Financial numbers in USD